Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Shares Purchased by Bank of New York Mellon Corp

Bank of New York Mellon Corp raised its holdings in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 0.8% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 481,386 shares of the specialty pharmaceutical company's stock after purchasing an additional 3,635 shares during the quarter. Bank of New York Mellon Corp owned 0.79% of Jazz Pharmaceuticals worth $59,764,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of JAZZ. Quadrant Capital Group LLC raised its holdings in shares of Jazz Pharmaceuticals by 97.1% in the 4th quarter. Quadrant Capital Group LLC now owns 205 shares of the specialty pharmaceutical company's stock valued at $25,000 after buying an additional 101 shares during the period. Elequin Capital LP grew its stake in Jazz Pharmaceuticals by 677.8% during the 4th quarter. Elequin Capital LP now owns 210 shares of the specialty pharmaceutical company's stock worth $26,000 after purchasing an additional 183 shares in the last quarter. CoreFirst Bank & Trust acquired a new position in Jazz Pharmaceuticals during the 4th quarter worth $28,000. Allianz SE acquired a new position in Jazz Pharmaceuticals during the 4th quarter worth $29,000. Finally, Parallel Advisors LLC grew its stake in Jazz Pharmaceuticals by 85.6% during the 1st quarter. Parallel Advisors LLC now owns 258 shares of the specialty pharmaceutical company's stock worth $32,000 after purchasing an additional 119 shares in the last quarter. Hedge funds and other institutional investors own 89.14% of the company's stock.

Insider Buying and Selling

In other news, Director Seamus Mulligan acquired 100,000 shares of the company's stock in a transaction that occurred on Friday, May 9th. The stock was purchased at an average cost of $98.26 per share, with a total value of $9,826,000.00. Following the purchase, the director directly owned 100,000 shares of the company's stock, valued at approximately $9,826,000. This trade represents a ∞ increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Bruce C. Cozadd sold 1,000 shares of the firm's stock in a transaction that occurred on Thursday, May 1st. The shares were sold at an average price of $116.35, for a total value of $116,350.00. Following the completion of the transaction, the chief executive officer directly owned 439,307 shares of the company's stock, valued at $51,113,369.45. The trade was a 0.23% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 2,500 shares of company stock valued at $277,930. Company insiders own 4.30% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the company. Morgan Stanley lowered their price objective on Jazz Pharmaceuticals from $183.00 to $166.00 and set an "overweight" rating for the company in a research report on Wednesday, May 7th. Royal Bank Of Canada decreased their target price on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Needham & Company LLC reissued a "buy" rating and issued a $202.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, June 11th. Piper Sandler reissued an "overweight" rating and issued a $147.00 target price (down from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Finally, Wall Street Zen cut Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 15th. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to data from MarketBeat.com, Jazz Pharmaceuticals currently has an average rating of "Moderate Buy" and an average target price of $184.00.

Jazz Pharmaceuticals Stock Performance

JAZZ traded down $2.21 on Friday, hitting $110.27. 404,731 shares of the company traded hands, compared to its average volume of 831,492. The stock has a market capitalization of $6.67 billion, a PE ratio of 14.70, a PEG ratio of 4.76 and a beta of 0.32. The company has a 50 day moving average of $108.32 and a 200-day moving average of $118.55. Jazz Pharmaceuticals PLC has a 12-month low of $95.49 and a 12-month high of $148.06. The company has a quick ratio of 2.97, a current ratio of 3.38 and a debt-to-equity ratio of 1.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its earnings results on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.65 by ($2.97). The business had revenue of $897.84 million for the quarter, compared to analysts' expectations of $984.16 million. Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. The business's quarterly revenue was down .5% on a year-over-year basis. During the same period last year, the company posted $2.68 earnings per share. Sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current year.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.